Tyra Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CARLSBAD, Calif., Sept. 17, 2021 /PRNewswire/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced the…
